Results: Six hundred and thirteen MRSA carriers underwent one or more decolonization treatments during the study period, mostly after hospital discharge. Decolonization was achieved in 367 (60%) patients with one eradication attempt and ultimately 493 (80%) patients were decolonized, with a median time until decolonization of 10 days (interquartile range 7 -43 days). Three hundred and twenty-seven (62%) carriers were treated according to the guideline, which was associated with an absolute increase in treatment success of 20% [from 45% (91/203) to 65% (214/327)].
Introduction
Colonization is an important step in the pathogenesis of Staphylococcus aureus infections and is instrumental in the nosocomial epidemiology of these bacteria. Approximately 20% of healthy people are persistently colonized with S. aureus, most frequently in the anterior nares, but other body sites, such as the perineum and throat, may be colonized as well. Another 30% are intermittently colonized and the remaining 50% appear, for unknown reasons, not susceptible to S. aureus carriage. 1 Carriage of S. aureus rarely causes disease in healthy people, but is associated with an increased risk of S. aureus infections in various patient populations. 1 Methicillin-resistant S. aureus (MRSA) has become endemic in healthcare institutions worldwide, with proportions of resistance among invasive S. aureus infections up to 70%, 2 -5 and most of these patients are colonized prior to infection. 6 Carriage of MRSA is associated with a higher risk of infection than carriage of methicillin-susceptible S. aureus (MSSA). 7 Without treatment, reported half-life times of MRSA carriage have been as long as 40 months. 8 -12 Eradication of MRSA carriage may serve two purposes; prevention of infection and prevention of transmission. Several eradication strategies have been proposed, but, to date, the optimal treatment schedule has not been defined. 13 A guideline for the treatment of carriage has been developed by the Dutch Working Party on Antibiotic Policy [Stichting Werkgroep Antibiotica Beleid (SWAB)], based on a systematic literature review and expert opinions, the conclusions and recommendations of which are summarized in Figure 1 and Table 1. 14 The guideline focuses on a distinction in treatment between uncomplicated and complicated carriage (the latter including MRSA infection, skin lesions, foreign-body material, mupirocin resistance and/or exclusive extranasal carriage), which was based mainly on expert opinion. 13, 14 In this observational study we evaluated the effectiveness of a standardized regimen for decolonization of MRSA carriers and determined adherence to the guideline in daily medical practice.
Methods

Study design, study setting and study population
We conducted a multicentre prospective observational cohort study of patients with microbiologically confirmed MRSA colonization, without influencing current medical care. Since decolonization had been the standard of care in the Netherlands for years, a placebo-controlled randomized design was considered unfeasible. As part of a nationwide MRSA control policy, screening for MRSA carriage by analysis of nose, throat and perineal swab samples is routinely performed in the Netherlands in individuals (patients and healthcare workers) who (i) are transferred from areas where MRSA is endemic, (ii) have a history of MRSA colonization, (iii) have been in contact with a known MRSA carrier or (iv) are animal (pigs and veal calves) farmers or their family members. In healthcare settings MRSA carriers are treated in isolation and offered eradication therapy, usually after hospital discharge. 15 In total, 18 medical centres, of which 5 were university hospitals, 11 were general teaching hospitals and 2 were regional laboratories, distributed throughout the Netherlands, participated. Eligible persons were those found to be colonized with MRSA during the study period, 1 October 2006 -1 October 2008, in whom decolonization treatment was started. The period of follow-up was 1 year at most. Anonymous case report forms (CRFs) were completed for all treated MRSA carriers. Limited information was collected from non-treated MRSA carriers.
Microbiological methods
Identification of MRSA and determination of antibiotic susceptibilities was performed according to the national guideline of the Dutch Society of Medical Microbiology. 16 Mupirocin susceptibility testing is routinely performed for all cultured MRSA strains. In this study, no distinction was made between low-and high-level resistance, since the definition of complicated carriage does not make a distinction. All participating hospitals used broth enrichment cultures, and swabs were obtained from nose, throat and (most of the time) perineum in all patients and from other sites (sputum, urine, skin lesions, catheter exit sites, blood etc.) on indication, both at the time of screening and during treatment follow-up. In four hospitals, swabs from the nose and throat with or without perineum were pooled, and additional site-specific cultures were obtained if the pooled sample grew MRSA. Genotyping of all MRSA isolates is performed by the National Institute for Public Health and the Environment (RIVM); from October 2006 to January 2008 by means of PFGE analysis and from January 2008 until the end of the study by means of Staphylococcus protein A gene (spa) typing. For the multivariate analysis we translated the PFGE type into the spa type (http://www.rivm.nl/earss) and pooled the spa types into seven common multilocus sequence types (MLSTs) and a rest group (http://spaserver2.ridom.de) (Table S1 , available as Supplementary data at JAC Online). ST398 was considered animal related. 17 As the prevalence of MRSA is very low in the Netherlands (both in hospitals and the community), it is not standard practice to genotype MRSA isolates recovered in follow-up cultures. In such cases, persistency of initial colonization is assumed. However, if colonization with a new type is suspected by the treating physician (e.g. because of phenotypic change or the presence of an external source), isolates will be genotyped. If strains appeared different from baseline isolates, such cases were considered acquisition of a new MRSA strain rather than failure to eradicate the initial colonizing strain. In this specific situation eradication was assumed adequate.
Ethical approval
The study was approved by the Institutional Review Boards of all participating hospitals. As decolonization was standard care before the start of the study, informed consent was not needed.
Definitions, data collection and variables of interest
MRSA carriage was defined as the presence of S. aureus containing the mecA gene from any body site, independent of the number of colonies or the presence of clinical signs of infection (from routine screening or clinical specimens). Complicated carriage was defined by the presence of at least one of the following: (i) the MRSA carrier has skin lesions or devices connecting the internal to the external environment or an MRSA-associated infection; (ii) MRSA is cultured only from extranasal sites (perineum, throat, wounds etc.); (iii) the MRSA isolate expresses in vitro resistance to mupirocin; or (iv) preceding treatments according to uncomplicated carriage failed. If none of these criteria was met, carriage was considered uncomplicated (Figure 1 ). For a group of patients, complexity of carriage could not be determined due to missing information on nasal carriage before the start of treatment (unknown complexity of carriage).
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Treatment according to the guideline In uncomplicated carriage, therapy had to meet the following criteria: (i) nasal application of an antibiotic to which the isolate expressed in vitro susceptibility and (ii) use of a disinfecting body wash (Figure 1) . In complicated carriage, therapy had to meet the following criteria: (i) nasal application of an antibiotic to which the isolate expressed in vitro susceptibility; (ii) use of a disinfecting body wash; and (iii) use of two oral antibiotics, one being rifampicin or fusidic acid, to which the isolate expressed in vitro susceptibility ( Figure 1 and Table 1 ). According to the guideline, carriers with repeated exposure to MRSA (e.g. those with professional animal contacts), or who are unlikely to be admitted to hospital settings in the near future, or who are not in close contact with patients or healthcare workers should not 14 a Treatment should not be given to patients with repeated exposure to MRSA (e.g. those with professional animal contacts) or to those that are unlikely to be admitted to hospital settings in the near future or are not in close contact with patients or healthcare workers. Furthermore, it is advised to first attempt to treat a complicating factor (e.g. skin disease or removal of devices) before starting an eradication attempt. To be categorized as complicated carriage, at least one of the following criteria needs to be present: (i) the MRSA carrier has skin lesions or devices connecting the internal to the external environment or an MRSA-associated infection; (ii) MRSA is only cultured at extranasal sites (perineum, throat, wounds etc.); (iii) the MRSA isolate expresses in vitro resistance to mupirocin; or (iv) preceding treatments according to uncomplicated carriage failed. If none of these criteria is met, carriage is called uncomplicated.
c Clean underwear, clothing, washcloths and towels daily and change of bed clothes every other day during treatment.
Antimicrobial eradication of MRSA in carriers 2411 JAC be treated. Furthermore, it was advised to treat or remove complicating factors (e.g. skin disease or devices), if possible, before starting eradication treatment.
Outcome Effective eradication after completion of treatment was defined as three consecutive negative sets of surveillance cultures (from nose, throat, perineum and other sites on clinical indication) obtained at least 48 h after completion of treatment and distributed over a period of at least 7 days. After successful MRSA decolonization, follow-up cultures were not requested, but were performed according to local protocols. If present, culture results from all sites at 3, 6 and 12 months (or at any other time interval if positive) were registered.
Statistical analysis
Descriptive statistics were calculated for baseline demographic and clinical variables. Univariate analysis was done using Fisher's exact tests to compare dichotomous variables, logistic regression to compare categorical variables and a Mann-Whitney U-test to compare age as a continuous variable. All analyses were carried out using SPSS version 15.0 (SPSS, Chicago, IL, USA).
Results
Study population
During the study period, 2027 new MRSA carriers were identified in the participating hospitals (median of 54 per centre; range 11 -463 per centre), of whom 690 (34%) received eradication treatment (median of 24 per centre; range 4-188 per centre). The reason for not starting treatment was unknown in 479 (36%) cases. Seventy-nine percent (679/858) of the remaining untreated carriers acquired MRSA from an animal source; 21% (179/858) did not receive eradication treatment due to complicating factors, became MRSA negative spontaneously, refused treatment, or were lost to follow-up or died (Figure 2) .
Of the 690 carriers in which eradication treatment was considered appropriate, 57 (8%) appeared not to be colonized when treatment started and 20 (3%) were lost to follow-up before three consecutive control culture sets were performed (Figure 2) .
Of the 613 remaining carriers, 121 (20%) were identified through clinical cultures and 492 (80%) through screening cultures. A presumed source of MRSA was reported in 79% of patients, most frequently a long-term care facility (LTCF) in the Netherlands (24%) and hospitals abroad (17%) or in the Netherlands (16%). Specific sites of carriage could not be distinguished in 133 carriers (22%), as all samples had been pooled. In 83 of these 133 carriers, no other complicating variable was present, and therefore the complexity of carriage could not be determined. In the remaining 480 carriers, prevalence of carriage in the nose, throat and perineum was 66%, 58% and 49%, respectively (Table 2 ). In all, 333 (54%) carriers were considered complicated at the time of first treatment, mainly because of skin lesions [153 (46%)] or non-nasal carriage [165 (50%)] ( Table 2 ). Concomitant carriage among household members was investigated in 131 of 380 (34%) index patients not treated in an LTCF, and carriage was demonstrated in 78 of 131 households (60%), yielding 87 carriers who were all included in this study. Reasons for screening household members were MRSA carriage in children (assuming intense contact with siblings and parents) and treatment failure. In 33% (43/131) of cases, carriage among household members was investigated before the start of topical treatment, in 45% (59/131) before the start of systemic treatment and in 6% (8/131) after failure of systemic treatment.
PFGE and/or spa type results were available for 599 of 613 (98%) isolates (Table S1 ). Fourteen percent (n¼ 88) were animalrelated strains (ST398). Other prevalent sequence types (STs) were ST5 (13%), ST8 (19%) and ST45 (15%). The presence of the Panton -Valentine leucocidin (PVL) gene was documented in 72 (14%) of 500 isolates; 21 ST8 (USA300) and 0 ST1 (USA400) strains.
Sixteen (3%) MRSA isolates were resistant to mupirocin (Table 2 ) and documented resistance rates to tetracyclines, co-trimoxazole, trimethoprim, rifampicin and fusidic acid were 26%, 10%, 23%, 1% and 1%, respectively. Susceptibility to glycopeptides was 100%.
Prescribed treatments and treatment results
The first treatment was successful in 367 (60%) carriers. Success rates were 61% (120/197), 56% (185/333) and 75% (62/83) (P ¼ 0.07), respectively, for uncomplicated carriage, complicated carriage and unknown complexity of carriage (unknown nasal carriage status). Sixty-two percent (327/530) of carriers for whom complexity of carriage was available were treated according to the guideline; success rates were higher among those treated according to the guideline versus those who were not, with an increase in absolute likelihood of treatment success of 20% [95% confidence interval (CI) 12% -28%] ( Table 2) . Nonadherence to the guideline during the first treatment course included no prescription of oral antibiotics (n¼ 167) or Among those in whom the first decolonization attempt failed or who were re-colonized (n ¼307), decolonization was achieved after a second treatment episode in 79% (n¼180/229). The median duration of follow-up after the second successful treatment was 191 days (IQR 92 -326 days, range 8 -365 days). Yet, among those, re-colonization with MRSA occurred in 37 patients (21%) after a median of 97 days (IQR 49 -128 days). Sixty-five patients (11%) underwent more than two decolonization courses.
Overall, 493 of 613 MRSA carriers (80%) were successfully decolonized with a mean of 1.5 (SD ¼ 0.7) decolonization cycles (range 1 -5 cycles). The median time until decolonization of the total cohort from start of treatment onwards was 10 days (IQR 7-43 days).
Among was documented at least 6 months after the last decolonization course. In three patients (0.5%) follow-up cultures yielded MRSA isolates resistant to mupirocin, whereas baseline isolates had been susceptible. Acquisition of resistance against one of the prescribed oral agents was not reported. Overall, 75 different treatment regimens were prescribed in 915 courses (Table S2 , available as Supplementary data at JAC Online). The guideline allowed different choices of antibiotic treatment, but strongly recommended mupirocin ointment unless mupirocin resistance had been documented. In fact, 99% of the patients received nasal mupirocin ointment (and chlorhexidine body wash) as first treatment. Only 14 of 613 patients received antibiotics that were not recommended as first treatment.
All patients received some form of topical treatment, most frequently mupirocin nasal ointment 
Discussion
MRSA eradication was achieved in 60% of 613 MRSA carriers after a single treatment course, and this increased to 80% after multiple courses, yielding an overall median time until decolonization of 10 days. Sixty-two percent of carriers were treated according to the guideline, which was associated with an absolute increase in treatment success of 20%. To the best of our knowledge this is the first study that evaluates a clinical guideline for treating MRSA carriage. The guideline in itself is unique in distinguishing complicated and uncomplicated carriers. The size, observational nature, long and complete follow-up and strain-specific analysis make the findings generalizable to a large population, although recolonization rates after successful decontamination might be different in other countries.
Effective eradication of MRSA after hospital discharge in colonized patients could be an important infection control measure. The epidemiology of hospital-acquired multiresistant pathogens (such as MRSA) is characterized by frequent readmissions of patients still colonized after their latest hospital discharge. This feedback-loop principle is considered crucial in maintaining nosocomial endemicity, which may lead to catastrophic control failures associated with high transmission rates. 18, 19 Reported median durations of MRSA carriage range from 8 to 40 months, but was 10 days (IQR 7 -43 days) after the start of treatment in this study.
Furthermore, colonized healthcare workers may contribute to nosocomial MRSA transmission, yet their role in the nosocomial dynamics of MRSA is less clear than that of colonized patients. In our study, 56% of colonized healthcare workers (of whom 72% were considered to have uncomplicated carriage) were successfully decolonized with a single course of topical treatment, (Table S2) . Our findings may also help to develop control strategies to contain the spread of community-acquired MRSA (CA-MRSA), which occurs predominantly outside healthcare settings.
The second objective of eradication is to prevent infections in patients who are at high risk (e.g. patients in the intensive care unit or patients scheduled for surgery). Pre-operative nasal decontamination with mupirocin nasal ointment was associated with reduced post-surgical staphylococcal infection rates in patients with documented nasal carriage of either MSSA or MRSA. 20, 21 Our final decolonization success rate of 80% is higher than most rates reported so far. 13 One explanation is that decolonization treatment was repeated and adapted if not successful on the first attempt and reasons for failure were evaluated (e.g. carriage in a household). On average, carriers received 1.5 courses, with 11% of patients undergoing more than two decolonization courses. Most other trials evaluated the efficacy of MRSA decolonization on the basis of a single decolonization course. In one smaller, single-centre cohort study, decolonization was completed in 54 of 62 patients (87%) after a mean of 2.1 (SD¼ 1.8) decolonization cycles (range 1 -10 cycles) using mupirocin nasal ointment, chlorhexidine mouth rinse and body wash for 5 days with additional oral antibiotics in the case of intestinal and urinary tract colonization. Other antibiotics were added if treatment failed. 22 A drawback of large-scale use of decontamination treatments is the emergence of resistance to the agents used. Eradication failures have been reported in patients colonized with MRSA strains with mupirocin resistance. 23 In our study, the rate of mupirocin resistance was low (3%) and 88% (14/16) of these patients were successfully decolonized. Moreover, documented development of mupirocin resistance was observed in 3 of 613 patients; no resistance development was documented for any of the other prescribed antibiotics. Yet, the possibility of resistance emergence is of concern and needs careful consideration of treatment indications and monitoring of bacterial susceptibilities.
This was a pragmatic, observational multicentre study, which has limitations. However, because of a national guideline for MRSA eradication, it would have been unethical to randomize patients to treatment that does not follow the guideline. Therefore, a prospective cohort design was considered the only possible design to evaluate the efficacy of the guideline. As such, the aim of the study was not to compare treatments, but to quantify the effects of the guideline. Furthermore, a placebo-controlled randomized trial might introduce a Hawthorne effect, which was avoided by not interfering with standard care practices in this observational design.
Other limitations are the lack of direct observation of patient adherence to prescribed treatments and monitoring the use of antibiotics for other reasons. In addition, it is not standard care to re-type MRSA strains if a patient becomes MRSA positive after a period during which cultures had remained negative. However, as MRSA prevalence rates in healthcare settings and the community in the Netherlands are very low, the risk of acquiring a new strain from such sources seems negligible. 24 Yet, it might be possible that some cases of presumed therapy failure were in fact episodes of newly acquired colonization after successful therapy. This would have biased our results to lower success rates of eradication therapy. Naturally, the risk of re-colonization could be higher in countries with high levels of MRSA in hospitals and the community, despite similar success rates of decolonization as reported in our study.
In conclusion, the results of this study indicate that MRSA carriers can be successfully decolonized and that adherence to the guideline increases the absolute likelihood of treatment success by 20%, with a median time until decolonization of 10 days.
